Xinqiao Hospital Of Chongqing
Clinical trials sponsored by Xinqiao Hospital Of Chongqing, explained in plain language.
-
MRNA technology takes on autoimmune diseases in new trial
Disease control Not yet recruitingThis early-phase study tests a new mRNA therapy for people with severe autoimmune diseases like lupus or immune anemia. The treatment uses lipid nanoparticles to deliver mRNA that targets and clears certain immune cells (B cells) to reduce disease activity. About 47 participants …
Phase: EARLY_PHASE1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated May 26, 2026 09:50 UTC
-
MRNA vaccine takes on Virus-Linked cancers in new early trial
Disease control Not yet recruitingThis early-phase trial tests an mRNA immunotherapy for people with tumors linked to the Epstein-Barr virus (EBV), such as nasopharyngeal cancer, gastric cancer, and certain lymphomas. The treatment aims to train the immune system to recognize and attack EBV-positive cancer cells.…
Phase: EARLY_PHASE1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
New drug combo aims to boost stroke recovery within 24 hours
Disease control Not yet recruitingThis study tests whether giving the drug eptifibatide soon after standard clot-dissolving treatment can help people with acute ischemic stroke recover better. About 786 adults who arrive at the hospital 4.5 to 24 hours after stroke symptoms start will be randomly assigned to rece…
Phase: PHASE3 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated May 22, 2026 13:51 UTC